GlassScriptPhysician profile
Argentina Leon
NPI 1225236896
$4,947.16
in general payments reported to CMS, 2019-2025
25 companies · $2,176 in 2025
The $2,176 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $603 · 2021: $169 · 2022: $149 · 2023: $382 · 2024: $1,084 · 2025: $2,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,562 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,561.86 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $530.70 | 2022-2025 | Opzelura |
| Abbvie INC. | $510.18 | 2019-2025 | |
| Genzyme Corporation | $376.31 | 2020-2025 | |
| Amgen INC. | $373.05 | 2019-2025 | Otezla, Otezla |
| Almirall LLC | $349.26 | 2024-2025 | Klisyri |
| Arcutis Biotherapeutics, INC. | $330.52 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $308.62 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $294.98 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Journey Medical Corporation | $227.64 | 2020 | |
| Lilly USA, LLC | $227.18 | 2019-2025 | Ebglyss, Taltz |
| Ucb, INC. | $215.06 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $205.58 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $186.57 | 2023-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $149.12 | 2020-2025 | |
| Galderma Laboratories, L.P. | $129.98 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $116.31 | 2024-2025 | |
| Dusa Pharmaceuticals, INC. | $87.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Leo Pharma INC. | $74.01 | 2025 | Adbry, Anzupgo |
| Organon LLC | $62.73 | 2025 | Nexplanon |
| Emd Serono, INC. | $25.39 | 2024 | |
| Dermira, INC. | $24.96 | 2020 | |
| Janssen Scientific Affairs, LLC | $21.37 | 2020 | |
| Cipher Pharmaceuticals US LLC | $20.62 | 2025 | Natroba, Spinosad |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.18 | 2025 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Argentina Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.